Gentel Biosciences commercially launched its APiX Chromogenic Protein Array system this week. The technology was previously available only in-house for Gentel's custom services business.
The system comprises a scanner with optional analysis software, proprietary surface chemistry substrates, and licensed detection reagents. In a statement, Gentel said the APiX Chromogenic offers flexibility and functionality to researchers who print their own arrays as well as those who purchase ready-to-use arrays and kits.
Alex Vodenlic, president and CEO of Gentel, added that the firm will launch "several" new APiX-based applications covering areas such as animal diagnostics, pathway analysis, cancer research, biomarker discovery, screening, and validation.